---
title: "Pre-market hot trades in US stocks: Veeva Systems -CL up 10.60% in pre-market; Meiwu Tech down 10.30% in pre-market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284877949.md"
description: "Veeva Systems -CL pre-market rose 10.60%; Meiwu Tech pre-market fell 10.30%; Cue BioPharma pre-market rose 54.68%; 22nd Century Group pre-market rose 50.67%; System1 pre-market rose 41.98%"
datetime: "2026-05-01T08:47:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284877949.md)
  - [en](https://longbridge.com/en/news/284877949.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284877949.md)
---

# Pre-market hot trades in US stocks: Veeva Systems -CL up 10.60% in pre-market; Meiwu Tech down 10.30% in pre-market

**Pre-market Hot Trades in US Stocks**

Veeva Systems is up 10.60% in pre-market trading. Based on recent key news:

1.  On May 1, Veeva Systems announced it would join the S&P 500 index, replacing Coterra Energy. This move triggered inflows from passive funds, pushing the stock price up by 9%. Source: Benzinga
    
2.  On May 1, Veeva Systems' growth score reached the 92nd percentile in the Benzinga Edge rankings, indicating strong growth potential and further supporting the stock price increase. Source: Benzinga
    
3.  On May 1, Evercore ISI analysts pointed out that Veeva may have structural advantages in the maturation of AI, enhancing market confidence in its future development. Source: MarketWatch The tech sector faces risks from AI disruptions and requires attention.
    

Meiwu Tech is down 10.30% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

**Top Gainers in Pre-market US Stocks**

Cue BioPharma is up 54.68% in pre-market trading. Based on recent key news:

1.  On April 30, Cue Biopharma announced the completion of a $30 million private placement. Following this announcement, the market is filled with confidence in the company's future development, driving the stock price significantly higher.
    
2.  On April 30, Cue Biopharma appointed Shao-Lee Lin as the new CEO. Shao-Lee Lin's extensive experience and leadership capabilities are viewed positively by the market, further boosting investor confidence.
    
3.  On May 1, Cue Biopharma disclosed specific details of the private placement, expected to complete the transaction on May 4. This news further solidified the market's optimistic expectations regarding the company's financial situation. The biopharmaceutical industry has performed strongly recently, with evident capital inflows.
    

22nd Century Group is up 50.67% in pre-market trading. Based on recent news:

1.  On April 29, 22nd Century Group shared its vision for growth in its VLN® products and leadership in tobacco harm reduction by 2026. This news boosted market confidence, driving the stock price significantly higher.
    
2.  On April 29, 22nd Century Group announced it would release its Q1 2026 financial report on April 30, expecting revenue of $4.61 million and earnings per share of -$1.20. Investors are eagerly anticipating the upcoming financial report, further driving the stock price up.
    
3.  On April 30, 22nd Century Group released related content via GlobeNewswire, emphasizing the company's leadership position in tobacco harm reduction. This news further enhanced market confidence in the company, leading to continued stock price increases. The tobacco industry has performed strongly recently, attracting high investor attention System1 pre-market rose by 41.98%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation

### Related Stocks

- [VEEV.US](https://longbridge.com/en/quote/VEEV.US.md)
- [WNW.US](https://longbridge.com/en/quote/WNW.US.md)
- [CUE.US](https://longbridge.com/en/quote/CUE.US.md)
- [XXII.US](https://longbridge.com/en/quote/XXII.US.md)
- [SST.US](https://longbridge.com/en/quote/SST.US.md)

## Related News & Research

- [Is It Time To Reconsider Veeva Systems (VEEV) After Recent Share Price Weakness](https://longbridge.com/en/news/287889250.md)
- [Merck KGaA, Darmstadt, Germany Selects Veeva Vault CRM Worldwide | VEEV Stock News](https://longbridge.com/en/news/287759763.md)
- [Veeva Systems (VEEV) to Release Quarterly Earnings on Wednesday](https://longbridge.com/en/news/287718555.md)
- [Veeva Announces Falcon, an Agentic Platform and Standard Agents to Deliver Agentic Labor in Drug Development | VEEV Stock News](https://longbridge.com/en/news/287759757.md)
- [Veeva Quality Cloud Advances Manufacturing Operations for Kindeva | VEEV Stock News](https://longbridge.com/en/news/287906171.md)